Atumelnant for the potential treatment of Congenital Adrenal Hyperplasia (CAH)
· Responsible for Global payer strategic planning to support value and access optimization for atumelnant as a potential first-in-class therapy for the potential treatment of Congenital Adrenal Hyperplasia (CAH).
· Partner cross-functionally and cross-regionally to develop and formulate global commercial strategic recommendations with aligned commercial input.
· Develop global P&MA strategy and pricing policy underpinning the global launch of atumelnant in CAH.
· Develop compliant strategies to support and enable global patient access to atumelnant prior to the conclusion of formal reimbursement agreements, where permitted.
· Lead cross-functional initiatives to secure timely payer scientific advice in key global geographies to inform payer evidence generation planning.
· Provide high-quality access input to broader atumelnant global evidence generation strategies in collaboration with cross-functional partners to ensure that access is optimized globally.
· Develop and rollout global payer unbranded message platform in alignment with cross-functional initiatives to support payer disease awareness and market development in CAH.
· Develop high-quality payer value communication materials to optimize the potential global access launch of atumelnant in CAH (including branded payer value narrative, rollout and training, price messaging, pricing objection handler)
· Ensure that atumelnant LCM initiatives and potential future indications are optimized for access.
· Represent GVAS and embed the global payer perspective in cross-functional atumelnant operating teams and workstreams as relevant.
•
Support P&MA capability building and thought leadership projects that advance knowledge of and readiness for the rapidly evolving Global payer environment
· Maintain industry awareness and proactively address changes in market trends, competition, product acceptance and new product releases and adjust Market Access plans accordingly
Palsonify (paltusotine) for the treatment of Acromegaly
· Support ongoing global commercialization efforts and reimbursement negotiations for Palsonify, including negotiation strategy, financial considerations, identification and prioritization of evidence required to sustain value over time.
· Support global P&MA governance including input to price policy, governance framework and negotiation business cases.
· Responsible to ensure that payer perspective is embedded in ongoing LCM initiatives including input into development strategy, evidence generation and commercialization priorities.